DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Marketable Securities

Note 4 - Marketable Securities

6 Months Ended

Jun. 30, 2023

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

4. Marketable Securities

The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):

	Fair Value Measurements Using Inputs Considered as of:
	June 30, 2023								December 31, 2022
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Commercial paper and corporate bonds	$	21,681	$	—	$	21,681	$	—	$	14,209	$	—	$	14,209	$	—
Government securities		33,144		—		33,144		—		14,565		—		14,565		—
Total	$	54,825	$	—	$	54,825	$	—	$	28,774	$	—	$	28,774	$	—

Accrued interest receivable on marketable securities is included in amounts receivable and was $186,000 and $80,000 as of June 30, 2023 and December 31, 2022, respectively.

There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2023.

Under the terms of the Company’s investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than 18 months and the amortized cost of all securities approximated fair value as of June 30, 2023 and December 31, 2022.